A23V 2250/2108
Caffeine, coffee extract
A23V2250/2108 (Caffeine, coffee extract) appears on 12 US grants and 27 published applications in this corpus.
Search patents in A23V- Granted patents
- 12
- Published applications
- 27
- Assignees
- 14
- Inventors
- 42
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 1 | 0 |
| 2016 | 0 | 0 |
| 2017 | 1 | 1 |
| 2018 | 2 | 4 |
| 2019 | 0 | 9 |
| 2020 | 3 | 1 |
| 2021 | 1 | 3 |
| 2022 | 0 | 2 |
| 2023 | 2 | 2 |
| 2024 | 0 | 1 |
| 2025 | 1 | 1 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Method of making composition including encapsulated caffeine14 Jul 2026US 12,678,441 B2Altria Client Services LLC
- Edible composition for alleviating visual fatigue14 Oct 2025US 12,440,532 B2Shanghai Lytone Biochemicals, LTD.
- Deuterated caffeine and uses thereof6 Jun 2023US 11,666,073 B2Lennham Pharmaceuticals, Inc.
- Deuterated caffeine and uses thereof10 Jan 2023US 11,547,127 B2Lennham Pharmaceuticals, Inc.
- Oral energy products including encapsulated caffeine1 Jun 2021US 11,020,401 B2Altria Client Services LLC
- Compositions and methods for masking off-notes in consumables7 May 2026US 2026/0123657 A1Givaudan SA
- Deuterated caffeine and uses thereof7 Aug 2025US 2025/0248424 A1Lennham Pharmaceuticals, Inc.
- Deuterated caffeine and uses thereof29 Aug 2024US 2024/0284942 A1Lannham Pharmaceuticals, Inc,
- Deuterated caffeine and uses thereof23 Nov 2023US 2023/0371555 A1Lennham Pharmaceuticals, Inc.
- Edible composition for alleviating visual fatigue16 Feb 2023US 2023/0048358 A1Shanghai Lytone Biochemicals, LTD.
Most cited
By later US patents
- Oral energy products including encapsulated caffeine36US 10,149,850 B2Altria Client Services LLC · 2018
- Beverage ice and related methods7US 9,192,189 B12015
- Deuterated caffeine and uses thereof4US 10,582,716 B1Lennham Pharmaceuticals, Inc. · 2020
- Deuterated caffeine and uses thereof3US 10,765,130 B1Lennham Pharmaceuticals, Inc. · 2020
- Ultra low dose nutraceutical compositions for enhancing sleep quality and treating sleep disorders2US 9,549,982 B2Foundational Biosystems, LLC · 2017